Based on the monoaminergic hypothesis for cognitive impairments, reducing Tat-induced dysregulation of not only DAT but also NET by allosteric modulators established their potential for therapeutic application in HAND. This evidence concerns the gene SLC6A2 and HIV-associated neurocognitive disorder.